🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing worldwide, with data suggesting in excess of 82 million infections annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

According to results detailed in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The study included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have voiced positive views. The availability of a single-dose, oral treatment like this is hailed as a "revolutionary step" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.